Biomarkers are one of the most exciting and fast-evolving areas in multiple sclerosis research, offering promise for earlier diagnosis, accurate prognosis, and truly personalised treatment. Yet despite their potential, there is still significant debate that limits their widespread application in clinical and research settings. In this episode, host Brett Drummond is joined by two leading voices in this field, Professor Charlotte Teunissen of Amsterdam UMC in The Netherlands and Associate Professor Michael Khalil of Medical University of Graz in Austria to explore the most promising biomarker candidates and when and how they might be implemented.

Over the past few years, the MS research community has been following developments in a new class of therapies called Bruton's tyrosine kinase inhibitors (BTKis). At ECTRIMS 2024, the results of two tolebrutinib trials were presented as late-breaking abstracts by Dr. Robert Fox, Neurologist at the Mellen Center for Multiple Sclerosis at Cleveland Clinic in the US, and Dr. Jiwon Oh, Neurologist at St. Michael's Hospital at the University of Toronto. The full results were recently published in The New England Journal of Medicine. In this episode, host Brett Drummond of MStranslate spoke with Drs. Oh and Fox about the outcomes and what they mean for people with MS.

What do the latest research findings tell us about the role diet can play in the management of multiple sclerosis (MS)? How should neurologists talk about diet with their patients?

While people living with MS may view their food choices as a way to exert some control over the disease, the concept of an "ideal diet" remains hotly contested. Dr. Brigit de Jong, Neurologist at MS Center Amsterdam, investigates non-pharmacological interventions, including diet, that determine the clinical outcome and pathogenesis of MS. She joins host Brett Drummond of MSTranslate to discuss the latest evidence on dietary modifications and how they should be communicated and implemented by neurologists.